PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: AnaSpec, Inc.

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

AnaSpec Introduces Fluorescent Endothelin GO Peptides - AnaSpec is pleased to announce the release of new HiLyte Fluor™ 488 and 5-FAM labeled Endothelin peptides (human, bovine, porcine, rat) adding on its Endothelin peptides collection
AnaSpec Introduces Fluorescent Endothelin GO Peptides


NewswireToday - /newswire/ - Fremont, CA, United States, 2010/10/21 - AnaSpec is pleased to announce the release of new HiLyte Fluor™ 488 and 5-FAM labeled Endothelin peptides (human, bovine, porcine, rat) adding on its Endothelin peptides collection.

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Endothelins (ET) are highly potent vasoconstrictor proteins distributed throughout all areas of the body, and are implicated in a number of conditions and diseases.1 Members of the Endothelin family of peptides consist of Pre-pro-endothelin-1, a biologically inactive precursor form cleaved by furin covertase to produce Big Endothelin-1 (Big ET-1), which is cleaved again by endothelin converting enzyme (ECE) between Trp-21 and Val-22 to yield the active ET-1 (1-21).2 Alternatively, pulmonary chymase is also capable of generating ET-1 (1-31) by cleaving the Tyr31–Gly32 bond of big ET-1.2, 3 Isoforms include ET-2, ET-3, and ET-4.2 All have two disulfide bonds that hold them in a conical spiral shape.2 In addition to their vasoconstrictive properties, endothelins have inotropic and mitogenic properties.2 They influence salt and water balance, affect intracellular Ca2+ concentrations and signal transduction cascades, contract non-vascular smooth muscle, alter central and peripheral sympathetic activity, and stimulate the renin-angiotensin-aldosterone system.2-5

ETs are normally kept at stable levels in healthy individuals, but can become overexpressed, leading to high blood pressure, kidney disease, and numerous cardiovascular diseases such as pulmonary hypertension, cardiac hypertrophy, myocardial infarction, heart failure, and cerebral vasospasm.1, 2 ET disregulation is also a key component of tumorigenesis in several types of cancer.6

Fluorescently labeled endothelins have various applications in ET-related disease research. They are utilized as probes in visualizing intracellular processes and molecular interactions between ET-1 and potential ET-antagonists or inhibitors at the cellular level.7 They are also used for localizing and monitoring ECE activity and ET-receptor binding affinity via fluorescence fluctuation spectroscopy.8, 9 Specific ET isoform binding sites throughout the body may be studied using labeled ET. In addition, flow cytometry is used in combination with labeled ET to assay ET-receptor expression during different periods of the cell cycle,10 and in vivo and in vitro imaging of ET activity is capable with fluorescent ET.11 Overall, these unique peptides offer a wide range of approaches to further studying ET function and ET-related mechanisms.

1. Palma, BD. et al. Brazilian J. Med. Biol. Res. 35, 75 (2002).
2. Lüscher, T. Circulation 102, 2434 (2000).
3. Fecteau, M. et al. Hypertension 46, 87 (2005).
4. Inoue, A. et al. J. Biol. Chem. 264, 14954 (1989).
5. Highsmith, RF. et al. FASEB J. 9, 1196 (1995).
6. Smith, K. et al. Br. J. Cancer 88, 163 (2003).
7. Boese, G. et al. J. Cardiovasc. Pharmacol. 36, S44 (2000).
8. Heilker, R. et al. Biochem. 43, 9021 (2004).
9. Higuchi, K. et al. J. Biol. Chem. 266, 18352 (1991).
10. Kobayashi, S. et al. J. Biol. Chem. 273, 12584 (1998).
11. Clark, JC. et al. Br. J. Pharmacol. 159, 812 (2010).

About AnaSpec
AnaSpec ( is a leading provider of integrated proteomics solutions to the world’s largest biotech, pharmaceutical, and academic research institutions. With a vision for innovation through synergy, AnaSpec focuses on three core technologies: peptides, detection reagents, and antibodies.
AnaSpec recently joined forces with Eurogentec to provide an even broader spectrum of products and services to serve the worldwide life science community.

About Eurogentec
Eurogentec ( is a leading global supplier of innovative reagents, kits, specialty products and custom services to scientists in the life science, biotechnology, pharmaceutical and diagnostic markets. Eurogentec provides a wide range of expertize in small- and large-scale DNA, RNA, PCR and qPCR kits, peptide synthesis and antibody supply for research applications. Our ISO13485:2003-certified manufacturing facilities in Belgium provides a wide range of high value oligonucleotide-based components for diagnostic and therapeutic applications. Eurogentec’s Belgium manufacturing facility is complemented by additional production facilities in North America and Japan. Eurogentec is also an experienced Contract Manufacturing Organization (CMO) for Biopharmaceuticals, operating a full-service, state-of-the-art GMP facility in Belgium.
Eurogentec is a privately held company headquartered in Liège, Belgium, with subsidiaries in North America, France, Germany, the UK, the Netherlands and Switzerland and has additional production facilities in North America, Japan and Singapore. Eurogentec employs 400+ people globally.

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Written by / Agency / Source: AnaSpec, Inc.


Availability: All Regions (Including Int'l)


Traffic Booster: [/] Quick Newswire Today Visibility Checker


Distribution / Indexing: [+]

# # #

  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!

AnaSpec Introduces Fluorescent Endothelin GO Peptides

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Publisher Contact: Tiffany Kao - 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any AnaSpec, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Read Latest Articles From AnaSpec, Inc. / Company Profile

Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine
Somatuline® Autogel® 120 Mg Receives Japanese Approval for A New Indication for the Treatment of Gastro-entero-pancreatic Neuroendocrine Tumors
OTC Topical Drugs Market Size will Grow Profitably in the Near Future 2017-2025 Finds PMR
Bioinformatics Market Size to Expand at 20.4% CAGR through 2020 Reports Persistence Market Research
Australia Nitric Acid Market Expected to Reach at Value of $1.3B by 2024 End Says PMR
Commodity Chemicals Market Projected to be Resilient by 2020 Says Persistence Market Research
Cell Expansion Market Set to Garner Staggering Revenues by 2025 Reports PMR
Soft Tissue Sarcoma Treatment Market Revenue Predicted To Go Up by 2025 Finds Persistence Market Research
Persistence Market Research Publishes Biopharmaceutical Membrane Filtration Market Forecast Over 2017-2025
Global Tablet Processing & Packaging Equipment Market to Reach USD 5,268.8 Million by 2022

Boost Your Social Network
& Crowdfunding Campaigns

NewswireToday Celebrates 10 Years in Business


Visit  NAKIVO, Inc.


  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (